Abstract: Provided herein are organoids comprising decellularized placental vascular scaffold comprising, or consisting of, a decellularized placental vascular scaffold, and methods of making and using the same.
Type:
Application
Filed:
December 21, 2012
Publication date:
January 15, 2015
Applicant:
Anthrogenesis Corporation
Inventors:
Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
Type:
Grant
Filed:
July 13, 2011
Date of Patent:
January 6, 2015
Assignee:
Anthrogenesis Corporation
Inventors:
Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
Type:
Application
Filed:
February 14, 2014
Publication date:
December 25, 2014
Applicant:
Anthrogenesis Corporation
Inventors:
James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
December 23, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
Abstract: The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
Type:
Grant
Filed:
May 17, 2012
Date of Patent:
November 25, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
Casper Paludan, James Edinger, Ryhor Harbacheuski, RoseAnn Murray, Robert J. Hariri
Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.
Type:
Grant
Filed:
March 2, 2009
Date of Patent:
November 18, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
Robert J. Hariri, David I. Stirling, Laure A. Moutouh-De Parseval, Kyle W. H. Chan
Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
Type:
Grant
Filed:
May 9, 2012
Date of Patent:
November 4, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
Type:
Application
Filed:
March 18, 2014
Publication date:
October 30, 2014
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
Abstract: The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing.
Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
Type:
Application
Filed:
October 11, 2013
Publication date:
September 11, 2014
Applicant:
Anthrogenesis Corporation
Inventors:
Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
Abstract: Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
Type:
Grant
Filed:
August 18, 2011
Date of Patent:
September 2, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
Abstract: Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.
Type:
Application
Filed:
September 16, 2013
Publication date:
August 7, 2014
Applicant:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Steven Alan Fischkoff, Aleksandar Francki, Vladimir Jankovic, Bitao Liang, Philippe Martin, Cynthia Ray, Xiaockui Zhang
Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
Type:
Grant
Filed:
May 13, 2011
Date of Patent:
June 17, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
Abstract: Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.
Type:
Grant
Filed:
August 24, 2009
Date of Patent:
May 20, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
Sascha D. Abramson, Marian Guelakis, Mohammad A. Heidaran, Kristen Labazzo, Shmuel Yaccoby
Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
Type:
Grant
Filed:
May 24, 2012
Date of Patent:
April 8, 2014
Assignee:
Anthrogenesis Corporation
Inventors:
James Edinger, Qian Ye, Jai-Lun Wang, Robert J. Hariri
Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
Type:
Application
Filed:
August 13, 2012
Publication date:
April 3, 2014
Applicant:
ANTHROGENESIS CORPORATION
Inventors:
Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
Type:
Application
Filed:
September 16, 2013
Publication date:
January 16, 2014
Applicant:
Anthrogenesis Corporation
Inventors:
James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
Type:
Application
Filed:
September 11, 2013
Publication date:
January 9, 2014
Applicant:
Anthrogenesis Corporation
Inventors:
Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger